Medical/Pharmaceuticals
Mindray Unveils Project 2030 and Re-writes the Future of Women's Health Ultrasound at ISUOG
CANCUN, Mexico, Sept. 23, 2025 /PRNewswire/ -- On September 15th, at ISUOG 2025 World Congress inCancun, Mexico, Mindray unveiled Project 2030, an initiative to improve global access to ultrasound technology. The project was launched to an international audience of leading specialists, capping a ...
2025-09-23 13:48
1170
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for review ...
2025-09-23 10:22
1424
GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) inSouth Korea for a Phase 1 clinical tria...
2025-09-23 09:41
1452
Korea's XR Startup DoubleMe To Reveal Breakthrough AI Technology at Tokyo XR Fair
DoubleMe, Korea's leading XR startup, to showcase its Next-Gen XR technologies to the Japanese wellness market inTokyo this Fall. SEOUL, South Korea, Sept. 23, 2025 /PRNewswire/ -- DoubleMe, a global pioneer in spatial computing and immersive technology, will visit the Autumn 2025 Tokyo XR Fair...
2025-09-23 09:00
1935
Angel Yeast's Breakthrough in Yeast Protein Research: AngeoPro Shown to Promote Calcium Absorption, Aiding in Osteoporosis Prevention
YICHANG, China, Sept. 23, 2025 /PRNewswire/ -- Angel Yeast
2025-09-23 09:00
798
With Millions of Children's Lives on the Line, Bill Gates Says Humanity Is at a Crossroads
At 2025 Goalkeepers event, Gates lays out roadmap for saving millions more children's lives by 2045 if governments stretch every dollar and scale a pipeline of affordable, lifesaving innovations Announces new pledge to the Global Fund 2026-2028 replenishment to prevent deaths from AIDS, TB, and ...
2025-09-23 08:00
1298
Sweden, the world's first travel destination on prescription
A new research-backed initiative sees physicians recommending trips to Sweden for the health benefits. STOCKHOLM, Sept. 23, 2025 /PRNewswire/ -- A sauna in Swedish Lapland for better sleep quality, or cold plunges in the archipelago for improved circulation? Two out of three respondents in a new...
2025-09-23 06:29
2423
IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training
MELBOURNE, Australia, Sept. 23, 2025 /PRNewswire/ -- IMRA Surgical, an Australian-based company at the forefront of disruptive technology for surgical training solutions announces a collaboration with Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") a global leader in radiopharmaceu...
2025-09-23 05:19
1662
Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets
* Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody * Findings highlight broad therapeutic applicability across oncology, immune, and metabolic diseases SEOUL, South Korea, Sept. 22, 2025 /PRNewswire...
2025-09-22 21:00
1774
Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeuti...
2025-09-22 21:00
1953
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS
2025-09-22 20:00
1551
LakeShore Biopharma Announces Transition to OTC Market Following Nasdaq Delisting
BEIJING, Sept. 22, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-22 20:00
2973
Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athenaa - Asia's First Dedicated Cancer Centre for Women
NEW DELHI, Sept. 22, 2025 /PRNewswire/ -- Apollo Hospitals Enterprise Ltd (AHEL) recently announced the launch ofApollo Athenaa – Asia's First Dedicated Cancer Centre for Women, located in E2-E3, Defence Colony, New Delhi. The centre was inaugurated by the Hon'ble Chief Minister ofDelhi, Smt. Rek...
2025-09-22 15:43
2278
PHASE Scientific Launches World's Largest Urine-Based Cervical Cancer (HPV) Screening Clinical Study, Marking New Era of Non-Invasive Cervical Cancer Screening
GUANG'AN, China, Sept. 22, 2025 /PRNewswire/ -- PHASE Scientific International Limited ("PHASE Scientific") today announced the official launch of the world's largest clinical study for urine-based cervical cancer (HPV) screening, with the first site established in Guang'an,Sichuan Province, Chin...
2025-09-22 15:39
1944
Akeso Announces First Patient Dosed in Registrational Phase II Study of TIGIT/TGF-β Bifunctional Antibody Fusion Protein AK130 Combined with Ivonescimab for Advanced Pancreatic Cancer
HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT/TGF-β bifunctional antibody fusion protein, in combination with ivonescimab ...
2025-09-22 14:51
1381
First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs
NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 onSeptember 19, ...
2025-09-22 12:29
1932
Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy
- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combinationwith semaglutide group compared to 57.1% in the sem...
2025-09-22 08:10
1635
WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends
SHANGHAI, Sept. 21, 2025 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, implemented its first interim dividend plan, d...
2025-09-22 08:00
1582
Antengene to Present Latest Preclinical Results from ATG-201 (CD19xCD3 TCE) at ACR 2025
SHANGHAI and HONG KONG, Sept. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic m...
2025-09-19 20:00
2441
European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injection 60 mg/mL and BILPREVDA® (denosumab) injection 120 mg...
2025-09-19 19:59
2657
Week's Top Stories
Most Reposted
One Universal Production Group (OUP) Officially Opens, Reinforcing Its Position as Asia's Leading IP Ecosystem and Tourism Company
[Picked up by 313 media titles]
2025-12-20 09:36
Singapore Airshow 2026 Marks 10th Edition with New Frontiers in Aviation and Space
[Picked up by 308 media titles]
2025-12-18 19:41
foodpanda Strengthens Merchant Care with Record Onboarding Milestone in Asia
[Picked up by 292 media titles]
2025-12-18 17:15Synvo AI and Sobat Bisnis Group (SBG) Forge Strategic Partnership to Bring Secure, Context-Aware Enterprise AI to Indonesia and Southeast Asia
[Picked up by 291 media titles]
2025-12-16 08:00
Colebrook Bosson Saunders Chooses India for First Executive Dialogue Exploring Future of Workspaces and Technology
[Picked up by 287 media titles]
2025-12-16 14:26
